Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2007
Sufficient subjects with a confirmed diagnosis of MS (EDSS score of 6.5 or below), will be recruited to ensure that 30 subjects (approx. equal numbers of each gender) complete the study. Subjects will undergo a screening visit, then four study days, each separated by a washout period of at least 7 days, when the different firategrast batches of drug substance will be administered, and a follow-up visit.
Epistemonikos ID: 79e9e479a3475fed39f70c8574ebc72c714564e5
First added on: Mar 31, 2022